Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-839 + Niraparib in Platinum-Resistant BRCA-wt Ovarian Cancer
NCT03944902Phase 1Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of telaglenastat in ovarian cancer (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Number and percent of treatment adverse events at 48 weeks. Started Sep 2021; status: terminated.
02
Drugs
telaglenastat
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03944902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944902.